Terazosin

• Description :

  Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

• CAS Number :

  [63590-64-7]

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Adrenergic Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Endocrinology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/terazosin.html

• Purity :

  98.5000

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4

• Molecular Formula :

  C19H25N5O4

• Molecular Weight :

  387.43

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

• References & Citations :

  [1]Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16 (1) :21-8.|[2]Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90 (5) :1763-8.|[3]Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48 (4) :300060520904851.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  α adrenergic receptor

• Citation 01 :

  Authorea. March 31, 2022.|Eur J Med Chem. 2024 Mar 5:267:116209.|Neurochem Int. 2021 Feb:143:104942.|Research Square Preprint. 2022 Jul.|Cell Prolif. 2025 Mar;58 (3) :e13764.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Res Sq. 2025 Mar 16.